Communiqués Celgene

Actions

CELG

Temps Différé Nasdaq Autres places de cotation 22:00:00 20/11/2019			Varia. 5j.	Varia. 1 janv.
108,24 ^USD	+0,10%		-1,97%	+68,89%

14/06/23	Sutro Biopharma, Inc. reçoit un avis de résiliation de Celgene Corporation	CI
22/12/20	Amgen signe un accord de licence avec Medicines Development for Global Health (développement de médicaments pour la santé mondiale)	MT

Communiqués

25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
04/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ
09/07/21	Besra Gold Inc: Announces Lodgment of Replacement Prospectus & Adjournment of Note Holder Meeting	NE
14/04/21	Celgene : Rocket docket pharma patent litigation taking off in Australia and other emerging trends	AQ
07/04/21	DGAP-WpÜG: Tender Offer / Target company: ; Bidder: qqqqq	EQ
25/03/21	Leonteq becomes new issuer on BX Swiss – “deriBX”	TE
07/07/20	BX Swiss AG receives approval from FINMA as Swiss Client Advisor Register	TE
03/07/20	Celgene : Parts Of Amended Patented Medicines Regulations Related To The PMPRB Struck Down	AQ
03/07/20	Furniture company mömax will be the new anchor tenant in the Rüti Center in Pratteln	TE
29/06/20	Celgene V. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2)	AQ
18/06/20	BX Swiss AG uses Blockchain technology to protect approved securities prospectuses against falsification	TE
28/05/20	BX Swiss AG receives approval from FINMA as a Prospectus Review Office	TE
22/11/19	Celgene : Announces Plans to Transfer Listing of Celgene's Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb	AQ
21/11/19	Celgene : Current report filing	PU
20/11/19	CELGENE CORP /DE/ : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/11/19	Celgene : Notification filed by National Security Exchange to report the removal from listing and registration of matured, redeemed or retired securities Initial Filing Amendments	PU
20/11/19	Celgene : Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb	BU
15/11/19	Celgene : Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma	BU
12/11/19	Skyhawk Therapeutics : Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing	PR
06/11/19	Celgene : to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting	BU
31/10/19	Celgene : Reports Third Quarter 2019 Operating and Financial Results	BU
16/10/19	Celgene : and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and Brain Health	BU
20/09/19	Celgene Corporation : Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients	BU
12/09/19	Celgene : Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints	BU